Latest Exelixis Inc. Stories
NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company.
LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Editor Note: For more information about this release, please scroll to bottom. LONDON, March 24, 2014 /PRNewswire/ -- On Friday, March 20, 2014, the NASDAQ Composite
NEW YORK, Sept.
Exelixis, Inc. (Nasdaq:EXEL) today reported preliminary phase 1 data from a dose-escalation trial of XL228 in patients with advanced malignancies (solid tumors, lymphoma, or multiple myeloma) for which standard therapies are no longer effective.
Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844.
- a meat pie that is usually eaten at Christmas in Quebec